International Alliance for Cancer Early Detection (ACED)

The University of Cambridge is part of the International Alliance for Cancer Early Detection (ACED), a science-led, collaborative investment of £55 million between Cancer Research UK, the Canary Center at Stanford University, the University of Cambridge, the Knight Cancer Institute at OHSU, University College London and the University of Manchester.

The purpose of ACED is to unite world-leading researchers to tackle the biggest challenges in the early detection of cancer, an important area of unmet clinical need. Please see the pages below for further information.

  • ACED Strategy Overview: Describes ACED's key aims, scientific strategy, primary contacts and ways to get involved.
  • Funding calls for collaborative projects and travel between ACED member centres will be announced regularly and detailed on our funding page. Cambridge researchers should read this Briefing note.
  • Current ACED projects involving Cambridge will be listed on our research projects page.
  • See our events page for ACED networking events and other opportunities.

ACED in Cambridge

Led by Professor Rebecca Fitzgerald, the Cambridge ACED member centre is leveraging the success of its Early Detection Programme to bring world-class facilities and early detection expertise to the wider Alliance. Central to this is the development of ACED Clinic Cambridge, which will provide Alliance members with the resources and infrastructure required to conduct first-in-human clinical testing of novel diagnostics and imaging devices.

PIs at Cambridge University can become a member of the ACED Cambridge Centre by contacting ACED Cambridge Programme Manager Wendy Alderton.

ACED Members can join the ACED Online Community to connect with researchers at other Centres and be involved with ACED opportunities. To receive an invitation to join, email

International Alliance for Cancer Early Detection (ACED) funding

Details about how to apply for funding through ACED.

ACED Clinic Cambridge

Providing world-leading resources and facilities to enable ACED members across the Alliance to conduct first-in-human clinical trials of new approaches to early cancer detection.

Regulatory advice for Alliance members

Guidance for ACED members across the Alliance on navigating the regulatory environment, so that new approaches to early cancer detection can be translated for patient benefit.